Day: January 29, 2026

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology  Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. (“Cortigent”), its wholly-owned subsidiary developing brain implant devices, presented the results of a 6-year Early Feasibility Study of the Orion® Visual Cortical Prosthesis System under development to deliver meaningful...

DALLAS, Jan. 29, 2026 (GLOBE NEWSWIRE) — P10, Inc. (NYSE: PX), (“P10” or the “Company”), and Bonaccord Capital Partners (“Bonaccord”), today announced a new collaboration with CAIS, the leading alternative investment platform for financial advisors. Bonaccord is a private equity firm focused on providing growth capital and strategic support to middle-market private markets sponsors, and this collaboration with CAIS provides advisors with expanded access to GP stakes solutions. “We’re excited to bring P10’s middle-market expertise to a broader audience of financial advisors and their clients,” said Luke Sarsfield, P10 Chairman and Chief Executive Officer. “This collaboration represents an important step in broadening our reach and supporting advisors as they incorporate GP stakes into their clients’ portfolios.” Bonaccord will join...

The base shelf prospectus is accessible, and the prospectus supplement will be accessible within two business days through SEDAR+ Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, British Columbia, Jan. 29, 2026 (GLOBE NEWSWIRE) — Versamet Royalties Corporation (“Versamet” or the “Company”) (TSX: VMET) has announced today that it has entered into an agreement with a syndicate of underwriters led by BMO Capital Markets and National Bank Capital Markets, under which the underwriters have agreed to buy on bought deal basis 9,100,000 common shares (the “Common Shares”), at a price of C$13.75 per Common Share for gross proceeds of C$125 million (the “Offering”). The Company has granted the Underwriters an option, exercisable at the offering price for a period of 30 days following the closing...

•              Preliminary assessment indicates potential for a rooftop solar system of up to approximately 60 kW. •              Pilot designed to evaluate technical feasibility and residential energy economics. •              Marks Springview’s first on-the-ground execution step toward scalable residential solar solutions in Singapore. Singapore, Jan. 29, 2026 (GLOBE NEWSWIRE) — Springview Holdings Ltd (Nasdaq: SPHL) (“Springview” or the “Company”), through its operating subsidiary Springview Enterprises Pte. Ltd., today announced a key milestone in its residential sustainability strategy with the identification of a corner terrace residential property at 15 Jalan Nipah, Singapore 488820 as a pilot project under its Memorandum of Understanding (“MOU”) with Jiangsu GSO New Energy Technology Co., Ltd. (“GSO”). The pilot project...

New York, Jan. 29, 2026 (GLOBE NEWSWIRE) — Digital Currency X Technology Inc. (Nasdaq: DCX) (the “Company”) today announced that it received a written notification (the “January Notice”), dated January 23, 2026, from the Listing Qualifications (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), that it has regained compliance with the market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2) (the “Rule”). The Company was previously notified on December 12, 2025 by the Staff that it had failed to maintain a minimum market value of listed securities of $35,000,000 over the previous 30 consecutive business days as required by the Rule. The January Notice stated that the Staff has determined that for the last 20 consecutive business days, from December 23, 2025 to January 22, 2026, the Company’s market...

DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The Agency has deemed the OLC resubmission to be a Class II complete response which has a six-month review period from the date of resubmission...

Low-power, 5V-capable devices deliver high performance while preserving low system complexity and costs CHANDLER, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) — Building on decades of experience in serving embedded applications where low power, affordability and ease of development are critical, Microchip Technology (Nasdaq: MCHP) has added PIC32CM PL10 MCUs to its PIC32C family of Arm® Cortex®-M0+ core devices. PL10 MCUs feature a rich set of Core Independent Peripherals (CIPs), 5V operation, touch capabilities, integrated toolsets and safety compliance. The device family targets high-volume applications including industrial control, building automation, consumer appliances, power tools and sensor-based systems. As part of the company’s unified MCU strategy, PL10 devices offer pin-to-pin compatibility with AVR® MCUs. The integrated Peripheral...

GOUVERNEUR, N.Y., Jan. 29, 2026 (GLOBE NEWSWIRE) — Titan Mining Corporation (TSX:TI, NYSE-A:TII), (“Titan” or the “Company”) today announced that it has filed a base shelf prospectus in Canada dated January 27, 2026 (the “Canadian Base Prospectus”) and a registration statement on Form F-10 (File No. 333-292602) (the “Registration Statement”) in the United States with the U.S. Securities and Exchange Commission (the “SEC”) under the U.S./Canada Multijurisdictional Disclosure System, providing the Company the flexibility to be able to raise up to US$150 million, from time to time, over a 25-month period, should it choose to do so. The filing does not mean that Titan is issuing shares today. Rather, it establishes a flexible financing framework that allows the Company to access capital efficiently in the future to support growth initiatives,...

BRANFORD, Conn., Jan. 29, 2026 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) announced today the tax treatment for the Company’s distributions on its common stock (CUSIP: 78590A109) and preferred stock (CUSIP: 78590A505) paid with respect to the calendar year ended December 31, 2025: COMMON STOCK TAX INFORMATION      Box 1a Box 1b Box 2a Box 3 Box 5               Record Date Payable Date Rate PerShare OrdinaryDividends PerShare QualifiedDividends PerShare Total CapitalGain PerShare NondividendDistributionPer Share Section 199ADividends PerShare3/17/2025 3/31/2025 $0.050000 $0.012362 $0.000000 $0.010840 $0.026798 $0.0123626/16/2025 6/30/2025 $0.050000 $0.012362 $0.000000 $0.010840 $0.026798 $0.0123629/15/2025 9/30/2025 $0.050000 $0.012362 $0.000000 $0.010840 $0.026798 $0.01236212/15/2025 12/30/2025 $0.050000 $0.012362 $0.000000 $0.010840 $0.026798 $0.012362  Total $0.200000 $0.049448 $0.000000 $0.043360 $0.107194 $0.049448 PREFERRED...

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled “Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet-Induced Obesity (DIO) Mouse Model” at Keystone’s conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects. Skye’s presentation addressed the following questions regarding the ability of its peripherally-restricted CB1-inhibitor antibody:Can nimacimab enhance optimal and suboptimal doses of incretin agonists? How durable is nimacimab’s effect on weight loss after treatment discontinuation? Can...